Bioline RX Ltd Sponsored ADR (BLRX) Price & Analysis

Compare

2,539 Followers

BLRX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.30 - $24.52

Previous CloseN/A

Volume8.80M

Average Volume (3M)29.73K

Market Cap

$16.97M

Enterprise Value$2.49M

Total Cash (Recent Filing)$19.56M

Total Debt (Recent Filing)$15.04M

Price to Earnings (P/E)―

Beta1.58

Next Earnings

Dec 01, 2025

EPS Estimate

-0.36

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.00

Shares Outstanding4,262,685

10 Day Avg. Volume22,062

30 Day Avg. Volume29,728

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.15

Enterprise Value/Revenue0.09

Enterprise Value/Gross Profit0.13

Enterprise Value/Ebitda0.64

Forecast

1Y Price Target

$19.00

Price Target Upside405.32% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical TrialsFavorable results from the use of motixafortide in a therapeutic combination in pancreatic cancer increase the likelihood that BLRX will find a development partner.

Financial PositionThe company ended the quarter with $28.2 million in cash, which management believes should provide runway into the first half of 2027.

Pipeline DevelopmentThe company is targeting a transaction to bolster its pipeline with a likely focus on oncology and rare disease.

Bears Say

Earnings ReportBioLineRx announced 2Q25 financial results, posting EPS of ($1.00) vs. the estimate of ($0.35), primarily due to warrant accounting adjustments.

Bioline RX Ltd Sponsored ADR News

BioLineRx, Hemispherian AS establish joint venture to develop GLIX1

BioLineRx (BLRX) and Hemispherian AS, a Norwegian biotech company focused on small molecule cancer therapeutics, announced the establishment...

2d ago

BLRX

BioLineRx and Hemispherian Launch Joint Venture to Develop GLIX1 for Glioblastoma

Bioline RX Ltd Sponsored ADR ( ($BLRX) ) has issued an update. On September 29, 2025, BioLineRx Ltd....

2d ago

BLRX

BioLineRx ADR Earnings Call: Optimism Amid Challenges

Bioline RX Ltd Sponsored ADR (($BLRX)) has held its Q2 earnings call. Read on for the main highlights...

1M ago

BLRX

BioLineRx: Strategic Pipeline Expansion and Strong Financial Health Justify Buy Rating

JonesTrading analyst Justin Walsh has reiterated their bullish stance on BLRX stock, giving a Buy rating yesterday. Justin...

2M ago

BLRX

BioLineRx Ltd. Reports Q2 2025 Financial Results

Bioline RX Ltd Sponsored ADR ( ($BLRX) ) has released its Q2 earnings. Here is a breakdown of...

2M ago

BLRX

BioLineRx: Promising Financial Position and Strategic Initiatives Drive Buy Rating

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Bioline RX Ltd Sponsored ADR, retaining the...

2M ago

BLRX

BioLineRx Reports Q2 2025 Financials and Strategic Updates

Bioline RX Ltd Sponsored ADR ( ($BLRX) ) has issued an announcement. On August 14, 2025, BioLineRx Ltd....

2M ago

BLRX

BioLineRx reports Q2 EPS 0c vs. 0c last year

Reports Q2 revenue $300K, consensus $661.33K. As of June 30, 2025, the company had cash, cash equivalents, and...

2M ago

BLRX

Options Volatility and Implied Earnings Moves Today, August 14, 2025

Today, several major companies are expected to report earnings: Applied Materials (AMAT), Bioline RX Ltd Sponsored ADR (BLRX),...

2M ago

BioLineRx Ltd. Approves Key Proposals at Annual Meeting

Bioline RX Ltd Sponsored ADR ( ($BLRX) ) has provided an announcement. On June 29, 2025, BioLineRx Ltd....

3M ago

BLRX

Promising Phase 2 Trial Results Drive Buy Rating for BioLine RX in mPDAC Treatment

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Bioline RX Ltd Sponsored ADR (BLRX – Research...

4M ago

BLRX

BioLineRx upgraded to Buy from Hold at JonesResearch

JonesResearch upgraded BioLineRx (BLRX) to Buy from Hold with a $12 price target The company announced new pilot...

4M ago

BLRX

BioLineRx Presents Promising Phase 2 Data at ASCO 2025 for Pancreatic Cancer Trial

Bioline RX Ltd Sponsored ADR ( ($BLRX) ) has issued an update. BioLineRx Ltd. announced promising new data...

4M ago

BLRX

BioLineRx announces new data from Phase 2 combination trial of motixafortide

BioLineRx (BLRX) announced that a poster including new data from the single-arm pilot phase of the investigator-initiated, randomized...

4M ago

BLRX

BLRX FAQ

What was Bioline RX Ltd Sponsored ADR’s price range in the past 12 months?

Bioline RX Ltd Sponsored ADR lowest stock price was $2.30 and its highest was $24.52 in the past 12 months.

What is Bioline RX Ltd Sponsored ADR’s market cap?

Bioline RX Ltd Sponsored ADR’s market cap is $16.97M.

When is Bioline RX Ltd Sponsored ADR’s upcoming earnings report date?

Bioline RX Ltd Sponsored ADR’s upcoming earnings report date is Dec 01, 2025 which is in 61 days.

How were Bioline RX Ltd Sponsored ADR’s earnings last quarter?

Bioline RX Ltd Sponsored ADR released its earnings results on Aug 14, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.353 by $0.353.

Is Bioline RX Ltd Sponsored ADR overvalued?

According to Wall Street analysts Bioline RX Ltd Sponsored ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bioline RX Ltd Sponsored ADR pay dividends?

Bioline RX Ltd Sponsored ADR does not currently pay dividends.

What is Bioline RX Ltd Sponsored ADR’s EPS estimate?

Bioline RX Ltd Sponsored ADR’s EPS estimate is -0.36.

How many shares outstanding does Bioline RX Ltd Sponsored ADR have?

Bioline RX Ltd Sponsored ADR has 4,262,685 shares outstanding.

What happened to Bioline RX Ltd Sponsored ADR’s price movement after its last earnings report?

Bioline RX Ltd Sponsored ADR reported an EPS of $0 in its last earnings report, beating expectations of -$0.353. Following the earnings report the stock price went down -4.315%.

Which hedge fund is a major shareholder of Bioline RX Ltd Sponsored ADR?

Currently, no hedge funds are holding shares in BLRX

Company Description

Bioline RX Ltd Sponsored ADR

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Bioline RX Ltd Sponsored ADR (BLRX) Earnings & Revenues

Historic Earnings Reports

BLRX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted significant progress in pipeline expansion and positive clinical trial outcomes, paired with successful cost management strategies. However, financial challenges persist, as evidenced by the net loss and dependency on royalty revenues. While the highlights suggest optimism for future growth, the financial and operational challenges maintain a balanced outlook.View all BLRX earnings summaries

BLRX Stock 12 Month Forecast

Average Price Target

$19.00

▲(405.32% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","18":"$18","35":"$35","9.5":"$9.5","26.5":"$26.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$26.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,9.5,18,26.5,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.75,5.461538461538462,7.173076923076923,8.884615384615383,10.596153846153847,12.307692307692307,14.019230769230768,15.73076923076923,17.442307692307693,19.153846153846153,20.865384615384613,22.576923076923077,24.288461538461537,{"y":26,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.75,4.923076923076923,6.096153846153847,7.269230769230769,8.442307692307693,9.615384615384617,10.788461538461538,11.961538461538462,13.134615384615385,14.307692307692308,15.480769230769232,16.653846153846153,17.826923076923077,{"y":19,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.75,4.384615384615385,5.019230769230769,5.653846153846153,6.288461538461538,6.923076923076923,7.5576923076923075,8.192307692307692,8.826923076923077,9.461538461538462,10.096153846153847,10.73076923076923,11.365384615384615,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":34.41,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.88,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.82,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.04,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.56,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.35,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.53,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.87,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >